EUVIMEDEUVIMED entdecken
Crossref

Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV ‐2 infection in children

Teng Liu iD, Jian-She Wang iD

Liver International · 2023

DOI: 10.1111/liv.15660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2023. Verfasst von Teng Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Liver Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims A recent study suggested that administration of ursodeoxycholic acid (UDCA) at dosages usually employed clinically may reduce rates of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. A recent surge of SARS‐CoV‐2 omicron infection in China allowed study of whether UDCA administration reduced susceptibility to SARS‐CoV‐2 infection in children with liver disease.

Methods

Through WeChat groups, a questionnaire was distributed to families ( n = 300) in which a child had been admitted to our liver service in the past 5 years. Among the families/households in which someone was infected with SARS‐CoV‐2, the proportion in which a child taking UDCA was infected was compared with the proportion in which a child not taking UDCA was infected.

Results

Of the 300 questionnaire answers, 280 (93.3%) were valid. SARS‐CoV‐2 infection was confirmed in 226 families (80.7%): 146 children were taking UDCA (10‐20 mg/kg/day) and 80 children were not taking UDCA. SARS‐CoV‐2 infection was confirmed in 95 children taking UDCA (65.1%) and in 51 children not taking UDCA (63.8%) ( p = 0.843); SARS‐CoV‐2 infection was suspected in 23 children taking UDCA (15.8%) and in 11 children not taking UDCA (13.8%) ( p = 0.687).

Conclusions

These results indicate that UDCA administration does not reduce susceptibility to SARS‐CoV‐2 infection in children with liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Liver DiseasesChildHumansSARS-CoV-2Ursodeoxycholic AcidHospitalization

Stichwörter der Autor:innen

COVID-19SARS-CoV-2UDCA

Substanzen

Ursodeoxycholic Acid

Autor:innen und Institutionen

  • The Center for Pediatric Liver Diseases, Children's Hospital of Fudan University, Shanghai, China.
  • Department of Pediatrics, Shanghai Medical College, Fudan University, Shanghai, China.

ORCID-Profile: Teng Liu, Jian-She Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, T., & Wang, J. S. (2023). Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV ‐2 infection in children. Liver International. https://doi.org/10.1111/liv.15660

Vancouver

Liu T, Wang JS. Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV ‐2 infection in children. Liver International. 2023. doi:10.1111/liv.15660

BibTeX
@article{Liu2023,
  author = {Liu, Teng and Wang, Jian-She},
  title = {Ursodeoxycholic acid administration did not reduce susceptibility to SARS‐CoV ‐2 infection in children},
  journal = {Liver International},
  year = {2023},
  doi = {10.1111/liv.15660}
}
Kostenlos starten →